Primitive neuroectodermal tumor
Drug research and approvals for primitive neuroectodermal tumor: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 141 studies of primitive neuroectodermal tumor are recruiting on ClinicalTrials.gov, and Health Canada has authorized 0 drug trials for it since 2013.
- Recruiting worldwide: 141
- Trials authorized in Canada: 0
- FDA orphan approvals: 0
- EU medicines: 0
- Naxitamab Enabled Transplant-Free Study in High-Risk NeuroblastomaNCT07932808 · Phase 2 · Giselle Sholler · starts Nov 26, 2026
- Prospective Multicenter Study of the Genomic, Transcriptomic, and Biological Profile of Patients With NeuroblastomaNCT07881172 · Not reported · Istituto Giannina Gaslini · starts May 12, 2022
- Cognitive Rehabilitation for Survivors of Childhood Medulloblastoma Using Real Time Hemodynamic NeurofeedbackNCT07830134 · Not applicable · St. Jude Children's Research Hospital · starts Jul 26, 2026
- Safety, Tolerability, and Preliminary Efficacy of [211At]MABG in Patients With Relapsed or Refractory NeuroblastomaNCT07767630 · Early Phase 1 · Sichuan University · starts Jul 21, 2026
- A Study of 177Lu-DTPA-Omburtamab in Children and Adolescents With Brain Cancer or Cancer That Has Spread to the Central…NCT07698899 · Phase 1 · Memorial Sloan Kettering Cancer Center · starts Jul 2, 2026
- Dinutuximab-beta and Chemotherapy in Newly Diagnosed High-Risk NeuroblastomaNCT07688252 · Phase 1 · Chang Gung Memorial Hospital · starts Jul 1, 2026
- Haploidentical Donor Cytokine-Induced Memory-Like Natural Killer Cells (CIML-NK) for Relapsed & Refractory NeuroblastomaNCT07635056 · Phase 2 · Children's Hospital Medical Center, Cincinnati · starts Dec 1, 2026
- Phase I Study of Becotatug Vedotin for Safety and Efficacy in EGFR-Positive Pediatric Relapsed/Refractory or Metastatic…NCT07584499 · Phase 1 · Sun Yat-sen University · starts May 30, 2026
- Patients Between the Ages of 12 Months to 21 Years With Newly-Diagnosed High-Risk Neuroblastoma Will Receive Children's…NCT07537400 · Phase 2 · Shaare Zedek Medical Center · starts Jun 23, 2026
How its trials ended
142 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 32 whose ending is known, 28% met their primary endpoint, 19% missed it and 53% stopped early.
- Completed, result not reported7351%
- Ongoing3021%
- Met its primary endpoint96%
- Stopped: other or unclear96%
- Status unknown75%
- Missed its primary endpoint64%
- Stopped: enrollment or feasibility54%
- Stopped: lack of efficacy21%
- Stopped: sponsor or business decision11%
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA